RankAlpha logo
Back to Rankings

SMMT

Summit TherapeuticsD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
+
Peers tracked
11
U.S. public peers
Grade Position
Below peers
vs peer average
SMMT vs peer average
40/100
SMMT vs. peer average (D vs. C)
Grade spread
A 1 · B 1 · C 4 · D 3 · F 2
Graded peers loaded
Coverage
11 graded
100% of tracked

Peer overview

MRK is the first available peer comparator.

Direct NSCLC immuno-oncology comparator because Summit's HARMONi-3 is designed against pembrolizumab plus chemotherapy, while Summit's 10-K also identifies Merck's sacituzumab tirumotecan among Phase III competitive candidates in first-line NSCLC [#10-K-2026-02-23].

✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
Top peerMRKMerck
SMMT
Summit Therapeutics
MRK
Merck
Grade
D
C
Momentum
13
41
Value
41
64
Sentiment
63
43
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Mixed
Open Side-by-Side ComparisonCompare all

Grade position vs MRK

SMMT / MRK
Grade Position
Below peers
SMMT vs. peer average (D vs. C)
40/100
Momentum
13
MRK
Value
41
MRK
Sentiment
63
SMMT

Rotation landscape

Peers ranked by the order returned from the peer source, with grades from the API.

Rank
Ticker
Company
Grade
Grade score
vs SMMT
1
MRK
MRK
C
60/100
-1
2
AZN
AZN
F
20/100
+1
3
PFE
PFE
D
40/100
Even
4
CRL
Charles River Laboratories International Inc Common
A
100/100
-3
5
RDY
Dr. Reddy's Laboratories Ltd ADR
D
40/100
Even
MRK is the first peer returned for this comparison set.